V
Vivette D. D’Agati
Researcher at Mayo Clinic
Publications - 15
Citations - 711
Vivette D. D’Agati is an academic researcher from Mayo Clinic. The author has contributed to research in topics: Nephrotic syndrome & Focal segmental glomerulosclerosis. The author has an hindex of 9, co-authored 15 publications receiving 633 citations. Previous affiliations of Vivette D. D’Agati include University of Washington.
Papers
More filters
Journal ArticleDOI
Differential expression of cyclin-dependent kinase inhibitors in human glomerular disease: role in podocyte proliferation and maturation.
Stuart J. Shankland,Frank Eitner,Kelly L. Hudkins,Tracy Goodpaster,Vivette D. D’Agati,Charles E. Alpers +5 more
TL;DR: Results show that podocyte quiescence may require the presence of the CDK inhibitors p27 and p57, and that p21 may have a multifactorial role in podocyte cell cycle regulation.
Journal ArticleDOI
Mayo Clinic/Renal Pathology Society Consensus Report on Pathologic Classification, Diagnosis, and Reporting of GN
Sanjeev Sethi,Mark Haas,Glen S. Markowitz,Vivette D. D’Agati,Helmut G. Rennke,J. Charles Jennette,Ingeborg M. Bajema,Charles E. Alpers,Anthony Chang,Lynn D. Cornell,Fernando G. Cosio,Agnes B. Fogo,Richard J. Glassock,Sundaram Hariharan,Neeraja Kambham,Donna J. Lager,Nelson Leung,Michael Mengel,Karl A. Nath,Ian S.D. Roberts,Brad H. Rovin,Surya V. Seshan,Richard J.H. Smith,Patrick D. Walker,Christopher G. Winearls,G B Appel,Mariam P. Alexander,Daniel C. Cattran,Carmen Avila Casado,H. Terence Cook,An S. De Vriese,Jai Radhakrishnan,Lorraine C. Racusen,Pierre Ronco,Fernando C. Fervenza +34 more
TL;DR: This consensus report emphasizes a pathogenesis-based classification of GN and provides guidelines for the standardized reporting of GN.
Journal Article
Cyclosporine treatment of lupus membranous nephropathy.
TL;DR: Six patients achieved a nadir proteinuria of less than 1 gram daily, two patients decreased urinary protein excretion to 1-2 grams daily, and the remaining two patients continued to excrete over 2 grams of protein daily.
Journal Article
Plasmapheresis treatment of recurrent FSGS in adult renal transplant recipients.
A Matalon,Glen S. Markowitz,R E Joseph,David Cohen,Stuart D. Saal,Bruce Kaplan,Vivette D. D’Agati,G B Appel +7 more
TL;DR: PP is less effective in adults than in children as a treatment for recurrent FSGS in the renal allograft and predictors of response to PP include early initiation of treatment after recurrence and possibly an early recurrence of disease.